Inhaled caspofungin for treating pneumocystis pneumonia
Part of Infections, Lungs & breathing clinical trials.
This trial tests a new inhaled medicine (caspofungin) added to standard treatment for Pneumocystis pneumonia, a serious lung infection. It may help fight the infection more effectively while you are already receiving oxygen and standard antibiotics.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of Pneumocystis pneumonia (a lung infection).
- You need to be on oxygen or breathing support and have started the standard treatment within the last 2 days.
- You must be able to receive treatment through a nebulizer (a machine that turns medicine into a mist you inhale).
- You cannot have any other active infections (except HIV), severe liver disease, or a history of serious skin reactions.
- You must be enrolled in the French healthcare system or equivalent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests caspofungin, a medicine, for treating Pneumocystis pneumonia (PCP) in people living with HIV. It aims to see if it works better than standard treatments.
This study compares different second-line antibiotics for treating Pneumocystis pneumonia (a serious lung infection) in people with weakened immune systems. It aims to find the best alternative when the standard treatment cannot be used.
This Phase 2 trial tests rezafungin, an antifungal medicine, to treat Pneumocystis pneumonia (PCP) in adults living with HIV. It may help people recover faster or more effectively from this serious lung infection.
This Phase 3 study tests whether low-dose trimethoprim-sulfamethoxazole (also called TMP-SMX) can treat Pneumocystis pneumonia (PCP) in people with weakened immune systems. It may help improve treatment while reducing side effects compared with standard dosing.
This trial tests a new way to diagnose pneumocystis, a lung infection that can affect people with weakened immune systems. It may help find the infection faster and more accurately using samples taken from your lungs.
This trial tests whether breathing in special viruses (called phages) that attack the Pseudomonas bacteria can help clear a serious lung infection in patients on ventilators. The treatment is added to standard antibiotics and may help fight the infection better.
Hear when a new Pneumocystis Pneumonia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.